Patrice Jean is an intellectual property attorney with over a decade of experience counseling leading and start-up pharmaceutical, chemical, and biotechnology companies in areas of patent law. In particular, she is adept at asserting and defending the patent rights underlying the core technologies and innovations of leading hi-tech and pharmaceutical companies, so as to protect and/or improve their access to multi-billion dollar markets. She also defends her clients against damages claims asserted by competitors, having spared them from paying billions of dollars in damages to date. As a patent prosecutor, Dr. Jean’s knowledge of the patenting process strengthens her litigation abilities, allowing her to argue the validity of her clients’ patents while challenging the validity of third-party patents.
Dr. Jean’s former experience as a research scientist informs her ability to advocate strongly for her clients as both a prosecutor and litigator. It positions her to not only understand the complex science behind her clients’ innovations but also the broader market implications of such technologies. Dr. Jean employs her scientific background and her strong grasp of client expectation to address the intellectual property challenges faced by her clients and to produce results that support their overall business objectives of remaining a leader in their respective fields.
Dr. Jean is known for her efforts to advance the progress of diversity in the legal profession. She is a 2014 Fellow of the Leadership Council on Legal Diversity, an organization of corporate chief legal officers and managing partners devoted to improving diversity in the legal profession. She is also a member of the firm’s Diversity Committee and a member of the National Bar Association.
Prior to entering the field of intellectual property law, Dr. Jean conducted research in various areas of biology and biochemistry including virology, oncology, kidney disease, X-ray crystallography, and narcotics addiction. Dr. Jean earned her Ph.D. in molecular biology, doing cancer research under Dr. Arnold J. Levine at Princeton University. Her doctoral thesis is entitled “Tissue, Strain, Gender and Age Variation in the Induction of p53 Activated Transcripts in Response to Cellular Stress.” After completing her graduate work at Princeton, Dr. Jean earned her J.D. at Columbia University School of Law where she was the editor-in-chief of the Science and Technology Law Review.
Outside of her career, Dr. Jean is dedicated to supporting all of the institutions of higher learning that she has attended. She is a former volunteer chair of Princeton Graduate Alumni Annual Giving and presently serves as leadership gifts vice-chair. She served as a co-chair of the Class of 2002 Columbia School of Law 10th Reunion Committee and is a Xavier University Class of 1993 class agent. She is a lifetime member of ABPA, the Association of Black Princeton Alumni.
- Teva in consolidated Hatch-Waxman litigations concerning proposed generic equivalents to Teva's blockbuster multiple sclerosis drug COPAXONE®. Achieved favorable claim construction rulings on behalf of Teva. Bench trials were held in July and September 2011 and a decision is pending. Teva Pharmaceuticals USA v. Mylan Pharmaceuticals et al. and Teva Pharmaceuticals USA v. Sandoz (S.D.N.Y.)
- Intervet in patent infringement litigation concerning patents related to porcine circovirus vaccine technology. Achieved favorable claim construction rulings. Wyeth v. Intervet (D. Del.)
- Intervet in patent litigation resulting in favorable ruling including summary judgment of non-infringement. Intervet v. Merial Limited et al. (D.D.C.)
- Teva Pharmaceuticals against multi-billion dollar damages claim in case relating to Pfizer’s epilepsy drug Neurontin® (gabapentin). Achieved favorable ruling including summary judgment rulings. Pfizer v. Teva Pharmaceuticals USA et al. (D.N.J.)
- Institut Pasteur and the Centre National de la Recherche Scientifique in patent litigation resulting in a favorable summary judgment ruling regarding ownership of a portfolio of 13 patents related to DNA “molecular combing” technology. The ruling confirmed that the world-renowned French research institutions are the rightful owners of the entire portfolio of patents. Institut Pasteur v. Simon (E.D. Pa.)
- “Protecting Life Science Inventions in View of the USPTO’s ‘Guidance for Determining Subject Matter Eligibility of Claims Reciting or Involving Law of Nature, Natural Phenomena, and Natural Products,’” Bloomberg BNA Life Sciences Law & Industry Report, April 4, 2014.
- “A Year of Changes for Life Sciences IP,” Law360, December 18, 2013.
- “Myriad: Practice Points and Considerations,” Intellectual Property Today, September 24, 2013.
- “Patent Law: Biotechnology Update,” American Bar Association, July 15, 2013.
- “Protecting Self-Replicating Biotechnologies in View of Bowman v. Monsanto,” Bloomberg BNA’s Patent, Trademark & Copyright Journal, June 14, 2013.
- “Myriad Ruling: Some Clarity, Some Uncertainty for Biotech,” Law360, June 14, 2013.